Pleiotropic effects of GLP-1 receptor agonists on peripheral artery disease: Is there any hope?

Review Biochemistry & Molecular Biology

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies

Irene Caruso et al.

Summary: Real-world studies have shown that GLP-1RA treatment has significant cardiovascular benefits compared to other glucose-lowering drugs, but it is less effective in preventing heart failure.

METABOLITES (2022)

Add to Collection

Editorial Material Endocrinology & Metabolism

GLP-1 RA and atrial fibrillation in the cardiovascular outcome trials

Zahra Hamedi et al.

DIABETES-METABOLISM RESEARCH AND REVIEWS (2021)

Add to Collection

Article Endocrinology & Metabolism

Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trial

Ehtasham Ahmad et al.

Summary: In this study, it was found that liraglutide had a favorable impact on certain cardiovascular biomarkers related to endothelial function compared to sitagliptin. These findings suggest potential differences in cardiovascular effects between these two agents.

DIABETES OBESITY & METABOLISM (2021)

Add to Collection

Article Endocrinology & Metabolism

Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study

Luca D'Onofrio et al.

Summary: This study demonstrates that both GLP1 RA and SGLT2i reduce the 10-year risk for cardiovascular disease in patients with T2D in primary cardiovascular prevention. The risk of CHD significantly decreased over 24 months with both treatments, with SGLT2i showing a more pronounced effect in the first 6 months.

DIABETES RESEARCH AND CLINICAL PRACTICE (2021)

Add to Collection

Review Endocrinology & Metabolism

The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update

Michael A. Nauck et al.

Summary: Incretin hormones GIP and GLP-1 play a significant role in insulin secretion and glucose tolerance in the gut-endocrine pancreas axis. They also have additional effects on bone remodelling, lipid storage, gastric emptying, and may provide benefits for cardiovascular complications and neurodegenerative disorders. Recent research on GIP/GLP-1 receptor co-agonists has renewed interest in the potential therapeutic applications of incretin hormones.

DIABETES OBESITY & METABOLISM (2021)

Add to Collection

Review Endocrinology & Metabolism